All In Biotech

Drug Trial Radar · NCT04370431

A Study of TTYP01 in Healthy Adult Subjects

A Phase I, Single Center, Randomized, Single-Ascending Dose, Pharmacokinetic and Safety Study (Part A), Bioavailability Comparison Study (Part B) and Food Effect Study (Part C) in Healthy Adult Subjects.

Last checked: Nov 19, 2026Latest source record: Jan 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Apr 24, 2020

Primary completion

Dec 17, 2020

Study completion Jan 8, 2021

Sponsor

Sponsor type
Industry
Collaborators
TIGERMED AUSTRALIA PTY LIMITED; CMAX Clinical Research Pty Ltd
First posted
May 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is integrated Phase 1, Single centre, Randomized study will be conducted in 3 parts, each with a specific primary objective: Part A: To characterise the safety and tolerability of TTYP01 in healthy adult subjects; Part B: To evaluate the bioavailability of TTYP01 tablets in healthy adult subjects; Part C: To characterise the food effect of TTYP01 tablets in healthy adult subjects under the fasted or fed condition. The secondary objectives of the study are to evaluate the pharmacokinetic (PK) profiles of TTYP01 tablets in healthy adult subjects, and the effects of gender on the PK of TTYP01 tablets in healthy adults. In Part A of the study, a total of 32 healthy adult subjects will be enrolled over four consecutive cohorts (8 per cohort), with participants receiving a single dose of TTYP01 at one of four levels (60, 120, 10 or 240 mg), to assess the PK and safety of TTYP01. In Part B, 16 healthy adults will be randomized into 2 groups, and the comparison of the PK of edaravone (TTYP01 and intravenous (IV) edaravone) will be evaluated using a randomized, open-label, four-period crossover design under fasted conditions. In the first crossover period, subjects will receive a single fixed dose of TTYP01 followed by the alternate IV dose after completion of the washout phase, and in the second crossover period, subjects will receive a higher fixed dose of TTYP01 followed by the alternate IV dose after completion of the washout phase. In Part C, 18 healthy subjects will be enrolled to evaluate the effect of food on the PK of TTYP01 using a randomized, open-label, two-period cross-over design. Participants will be randomized into two groups and administered a fixed dose of TTYP01 on Day 1 (Period 1) under the fed conditions and the second dosing day (Period 2) under the fasted conditions, while the other group being administered a fixed dose of TTYP01 on Day 1 (Period 1) under the fasted conditions and the second dosing day (Period 2) under the fed conditions.

Conditions

  • Healthy Adult Subjects

Interventions

  • TTYP01 single ascending dosesDrug

    TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)

  • PlaceboDrug

    Placebo control for Part A of the study

  • TTYP01, 60 mgDrug

    TTYP01 oral tablets (30 mg edaravone per tablet)

  • TTYP01, 120 mgDrug

    TTYP01 oral tablets (30 mg edaravone per tablet)

  • Radicut® (ampoule), 30 mgDrug

    An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes

  • Radicut® (bag) , 60 mgDrug

    An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes

  • TTYP01, up to 120 mgDrug

    TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: until the last follow-up visit, up to 4 weeks
  2. change in hemoglobin (g/L)Time frame: up to 6 days post each dose
  3. change in hematocrit (ratio)Time frame: up to 6 days post each dose
  4. change in red blood cell count (cells x 10^12/L)Time frame: up to 6 days post each dose
  5. change in white blood cell (WBC) count (cells x 10^9/L)Time frame: up to 6 days post each dose
  6. change in platelet count (cells x 10^9/L)Time frame: up to 6 days post each dose
  7. change in total neutrophils count (cells x 10^9/L)Time frame: up to 6 days post each dose
  8. change in lymphocytes count (cells x 10^9/L)Time frame: up to 6 days post each dose
  9. change in monocytes count (cells x 10^9/L)Time frame: up to 6 days post each dose
  10. change in eosinophils count (cells x 10^9/L)Time frame: up to 6 days post each dose
  11. change in basophils count (cells x 10^9/L)Time frame: up to 6 days post each dose
  12. change in serum sodium (mmol/L)Time frame: up to 6 days post each dose
  13. change in serum potassium (mmol/L)Time frame: up to 6 days post each dose
  14. change in serum chloride (mmol/L)Time frame: up to 6 days post each dose
  15. change in serum calcium (mmol/L)Time frame: up to 6 days post each dose
  16. change in serum glucose (mmol/L)Time frame: up to 6 days post each dose
  17. change in serum urea (mmol/L)Time frame: up to 6 days post each dose
  18. change in serum creatinine (umol/L)Time frame: up to 6 days post each dose
  19. change in serum total bilirubin (umol/L)Time frame: up to 6 days post each dose
  20. change in aspartate aminotransferase (AST) (U/L)Time frame: up to 6 days post each dose
  21. change in alanine aminotransferase (ALT) (U/L)Time frame: up to 6 days post each dose
  22. change in alkaline phosphatase (ALP) (U/L)Time frame: up to 6 days post each dose
  23. change in serum creatine kinase (CK) (U/L)Time frame: up to 6 days post each dose
  24. change in serum albumin (g/L)Time frame: up to 6 days post each dose
  25. change in serum phosphate (mmol/L)Time frame: up to 6 days post each dose
  26. change in serum lipase (U/L)Time frame: up to 6 days post each dose
  27. change in serum total protein (g/L)Time frame: up to 6 days post each dose
  28. change in urine pHTime frame: up to 6 days post each dose
  29. change in urine specific gravityTime frame: up to 6 days post each dose
  30. change in urine glucoseTime frame: up to 6 days post each dose
  31. change in urine proteinTime frame: up to 6 days post each dose
  32. change in urine ketonesTime frame: up to 6 days post each dose
  33. change in urine bloodTime frame: up to 6 days post each dose
  34. change in urine castsTime frame: up to 6 days post each dose
  35. change in urine crystalsTime frame: up to 6 days post each dose
  36. change in urine epithelial cellsTime frame: up to 6 days post each dose
  37. change in urine bacteria (cfu/L)Time frame: up to 6 days post each dose
  38. change in urine red blood cells (Cells x 10^9/L)Time frame: up to 6 days post each dose
  39. change in urine white blood cells (Cells x 10^9/L)Time frame: up to 6 days post each dose
  40. change in systolic blood pressure (mmHg)Time frame: up to 6 days post each dose
  41. change in diastolic blood pressure (mmHg)Time frame: up to 6 days post each dose
  42. change in pulse rate (bpm)Time frame: up to 6 days post each dose
  43. change in body temperature (celsius)Time frame: up to 6 days post each dose
  44. Change in QT intervals (msec)Time frame: up to 6 days post each dose
  45. Change in RR intervals (msec)Time frame: up to 6 days post each dose
  46. Change in PR intervals (msec)Time frame: up to 6 days post each dose
  47. Change in QRS duration (msec)Time frame: up to 6 days post each dose
  48. Change in corrected QTcF (msec)Time frame: up to 6 days post each dose
  49. clinically significant abnormality in brief physical examinationsTime frame: up to 6 days post each dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research Pty Ltd

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.